Human papillomavirus (HPV) infection, which poses significant disease burden, is decreasing following implementation of vaccination programs. Synthesized evidence on HPV vaccine real-world benefit ...

Bulgaria is among the European Union (EU) countries with the highest burden of cervical cancers and life expectancy below the EU average. The majority of cervical cancer cases (more than 95%) are caused by the human papillomavirus (HPV). The aim of this retrospective, cost of illness study is to identify direct healthcare costs of cervical cancer in Bulgaria from the payer perspective and to calculate indirect costs and the associated years of life lost. Costs data were sourced from the National Health Insurance Fund from January 2018 to December 2020. Years of life lost were calculated based on the country and gender-specific life expectancy. Indirect costs due to productivity loss were calculated using the human capital approach. The total treatment costs for 3540 patients with cervical cancer are EUR 5,743,657 (2018), EUR 6,377,508 (2019), and EUR 6,751,182 (2020). The costs associated with drug acquisition and administration accounted for the majority (63%) of total healthcare costs followed by hospital management costs (14%). An estimated total of 20,446 years of life were lost due to cervical cancer for the period 2018–2020. The costs of productivity losses are estimated at EUR 7,578,014. Our study showed that the economic burden of cervical cancer in Bulgaria is substantial. Focus on cervical cancer prevention via vaccination against the human papillomavirus, timely screening, early diagnosis, and higher vaccine coverage rates could reduce its economic burden in Bulgaria.

Human papillomavirus (HPV) is a prevalent sexually transmitted infection associated with various diseases, including genital warts, recurrent respiratory papillomatosis (RRP), and multiple pre-cancerous diseases and cancers. HPV causes over 90% of cervical cancer cases, the sixth most common cancer among women in China. To support the national plan for accelerating cervical cancer elimination through enhanced HPV vaccination and screening rates, China requires reliable data systems to monitor and evaluate progress effectively. We conducted a scoping review of literature from PubMed and the China National Knowledge Infrastructure databases, supplemented by government documents and news articles from the Internet, spanning April 2012 and July 2023. Our objective was to identify and summarize databases and data systems used for HPV-related real-world evidence generation in China. The identified data systems cover four primary domains: HPV vaccination, HPV screening, HPV-related cervical and non-cervical diseases, and sexual and lifestyle behaviors. Our review identified a total of 140 articles and 26 databases and data systems. These databases and data systems were categorized into the following reporting areas: HPV vaccination (n = 2), HPV screening (n = 2), HPV-related cervical and non-cervical diseases (n = 21), and sexual and lifestyle behaviors (n = 1). The Immunization Program Information Management System and the regional health care information platform in Ningbo provide HPV vaccination data, while KingMed Diagnostics and the “Two Cancers” Screening Platform track HPV screening at national level. Twenty-one systems were identified for tracking HPV-related cervical and non-cervical diseases, including head and neck cancers, penile lesions, and genital warts; however, no systems were found for anal, vulvar, or vaginal cancers, or RRP. One database, the National Human Immunodeficiency Viruses Epidemiology Database, included information on sexual and lifestyle behaviors. Pilot cities, including Yinzhou, Chengdu, Suzhou, and Lecheng, have implemented population-level data systems capable of identifying information on HPV vaccination, HPV screening, and HPV-related diseases. China has made significant progress in addressing HPV-related diseases and prevention, but more integrated and comprehensive data systems are needed to effectively support research, improve interventions, and achieve national and global goals in HPV prevention and cervical cancer elimination.

The introduction of effective human papillomavirus (HPV) vaccination, screening, and treatment programs has led the World Health Organization to call for the global elimination of cervical cancer. ...

Background: Persistent human papillomavirus (HPV) infection is a known cause of a subset of head and neck cancers (HNCs). In the last two decades, the proportion of HNCs attributable to HPV infection has increased worldwide, notably the oropharyngeal cancers. However, the trend of HPV-related HNC burden is not clearly understood yet in China. Thus, the absolute b u r den o f HPV-related he a d an d n e ck ca n cers in China (BROADEN-China) will be conducted to estimate the proportion of HNCs attributable to HPV infection, per anatomic site, by genotype, in three time periods (2008–2009, 2013–2014 and 2018–2019). Methods and analysis: BROADEN-China is a nationwide, multisite, cross-sectional study. A stratified, multistage, non-randomised cluster sampling method will be used to select 2601 patients with HNC from 14 hospitals across seven regions, based on population density in China. Patients with formalin-fixed paraffin-embedded tissue samples collected prior to treatment induction during three time periods will be included, and factors (eg, smoking status, alcohol consumption, betel nut chewing, Epstein-Barr virus, teeth loss, etc) associated with HNC will be assessed. HPV testing (HPV-DNA, HPV-mRNA and p16 ^INK4a immunohistochemistry) and histological diagnosis of the tissue samples will be conducted at a central laboratory. The study protocol and all required documents have been submitted for review and approval to the Independent Ethics Committees of all the participating sites. The informed consent was waived for all participants and all the recorded data will be treated as confidential. We have included 14 hospitals as our participating sites, of which Henan Cancer Hospital is the leading site. The study has been approved by the independent ethics committees of the leading site on 3 December 2020. The other 13 participating site names of ethics committee and IRB that have approved this study.